Vaccination with syngeneic monoclonal anti-idiotype protects against a tumour challenge.
Vaccination with syngeneic monoclonal anti-idiotype protects against a tumour challenge.
复制标题
同基因单克隆抗独特型疫苗接种可预防肿瘤攻击。
作者：
P. L. Dunn;C. Johnson;J. Styles;S. Pease;C. Dean
用两种肿瘤反应性的同基因单抗11/160和M10/76(分别针对蒙帽大鼠肉瘤HSN和MC24)免疫蒙罩大鼠，制备了分泌抗独特型单抗的杂交瘤。杂交瘤的选择是基于分泌的抗体与抗原竞争结合免疫独特型。已发现一种能识别抗体11/160的抗原结合位点独特位的抗独特型单抗(HIM/1/230，伽马2a同型)可替代抗原。用HIM/1/230三次挑战免疫的蒙面大鼠产生的血清ab3在抗原特异性上与11/160ab1没有区别，并且在静脉注射后显示出肿瘤摄取量的减少。挑战10(6)个HSN细胞。抗独特型疫苗的免疫应答在质量和数量上都与免疫方式有关。只有当疫苗含有弗氏佐剂时，才会产生高滴度的11/160样ab3，而只有在没有佐剂的情况下接种了抗独特型疫苗的动物才会对肿瘤攻击产生抵抗力。
Rat X rat hybridomas secreting monoclonal anti-idiotypic antibodies have been prepared from Hooded rats immunized with two tumour-reactive, syngeneic monoclonal antibodies 11/160 and M10/76 (specific, respectively, for the Hooded rat sarcomata HSN and MC24). The hybridomas were selected on the basis that the secreted antibodies competed with antigen for binding to the immunizing idiotype. One monoclonal anti-idiotype (HIM/1/230, gamma 2a isotype) that recognizes an antigen-binding site idiotope of antibody 11/160 has been found to substitute for antigen. Hooded rats vaccinated by three challenges with HIM/1/230 produce serum Ab3 that is indistinguishable in antigen specificity from the 11/160 Ab1, and show reduced tumour take following an i.v. challenge with 10(6) HSN cells. The response to vaccination with anti-idiotype was both qualitatively and quantitatively dependent on the mode of immunization. High titre 11/160-like Ab3 was generated only when the vaccine contained Freund's adjuvant, whereas resistance to tumour challenge was found only in animals vaccinated with anti-idiotype in the absence of adjuvant.